Research & development

Research and development expenses are the costs a company incurs to discover new knowledge, develop new products, or improve existing ones before those products are ready to sell. It sits below gross profit as an operating expense alongside selling, general & administrative expenses, meaning it is not tied to current production but to future revenue.

Under US GAAP, most R&D must be expensed as incurred rather than capitalised, so heavy R&D spending hits the income statement immediately and suppresses operating profit even when the work being funded may generate returns for decades. This is a known distortion when comparing R&D-intensive companies like pharma or semiconductors against asset-light businesses.

R&D as a percentage of revenue is one of the most watched ratios in technology, pharma, and industrial sectors. Too low and the company is harvesting its competitive position without reinvesting. Too high without a corresponding pipeline of commercial products signals poor capital discipline.

For early-stage companies R&D often exceeds gross profit entirely, making it the single largest driver of losses and the line investors scrutinise most closely when assessing whether spending is translating into durable product advantage.